NCT03702725: Phase 1: Study of Ibrutinib in Combination With Revlimid/Dexamethasone in RRMM Myeloma

• NCT03702725: Phase 1: Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma

Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma

Sponsor:

Alliance Foundation Trials, LLC.

Collaborator:

Pharmacyclics LLC.

Multiple Locations

This is a registration, open-label phase 1 study of the combination of ibrutinib/lenalidomide:/dexamethasone in women and men with relapsed/refractory multiple myeloma.

---

ClinicalTrials.gov Identifier: NCT03702725

Official Title: A Phase I Study of Ibrutinib (PCI-32765) in Combination With Revlimid/Dexamethasone (Rd) in Relapsed/Refractory Multiple Myeloma

First Posted : October 11, 2018

Click here to see details on ClinicalTrials.gov

---

Drug: Ibrutinib

Drug: Lenalidomide

Drug: Dexamethasone

---